74 related articles for article (PubMed ID: 19816961)
1. The clinical significance of tumor cells in bone marrow or apheresis product and the efficacy of CD34+ selection and high-dose chemotherapy in patients with Stage III breast cancer.
Arpaci F; Safali M; Ozet A; Ural AU; Cetin T; Ozturk M; Ataergin S; Kuzhan O; Komurcu S; Ozturk B; Acikel C
J Clin Apher; 2009; 24(5):197-204. PubMed ID: 19816961
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation.
Solano C; Badia B; Lluch A; Marugan I; Benet I; Arbona C; Prosper F; García-Conde J
Bone Marrow Transplant; 2001 Feb; 27(3):287-93. PubMed ID: 11277176
[TBL] [Abstract][Full Text] [Related]
3. Occult tumor cell contamination in patients with stage II/III breast cancer receiving sequential high-dose chemotherapy.
Viret F; Chabannon C; Sainty D; Genre D; Gonçalves A; Arnoulet C; Gravis G; Bertucci F; Houvenaeghel G; Jacquemier J; Bardou VJ; Ladaique P; Braud AC; Maraninchi D; Viens P
Bone Marrow Transplant; 2003 Dec; 32(11):1059-64. PubMed ID: 14625576
[TBL] [Abstract][Full Text] [Related]
4. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial.
Yanovich S; Mitsky P; Cornetta K; Maziarz RT; Rosenfeld C; Krause DS; Lotz JP; Bitran JD; Williams S; Preti R; Somlo G; Burtness B; Mills B
Bone Marrow Transplant; 2000 Jun; 25(11):1165-74. PubMed ID: 10849529
[TBL] [Abstract][Full Text] [Related]
5. Micrometastases in apheresis products predict shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT).
Syme R; Stewart D; Rodriguez-Galvez M; Luider J; Auer Y; Klassen J; Morris D; Brown C; Russell J; Glück S
Bone Marrow Transplant; 2003 Aug; 32(3):307-11. PubMed ID: 12858203
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease: correlation of CD34+ selection to clinical outcome.
Ahmed T; Kancherla R; Qureshi Z; Mittelman A; Seiter K; Mannancheril A; Puccio C; Chun HG; Bar M; Lipshutz M; Ali MF; Goldberg R; Preti R; Lake D; Durrani H; Farley T
Bone Marrow Transplant; 2000 May; 25(10):1041-5. PubMed ID: 10828863
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells.
Weaver CH; Moss T; Schwartzberg LS; Zhen B; West J; Rhinehart S; Campos L; Beeker T; Lautersztain L; Messino M; Buckner CD
Bone Marrow Transplant; 1998 Jun; 21(11):1117-24. PubMed ID: 9645574
[TBL] [Abstract][Full Text] [Related]
9. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R
Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897
[TBL] [Abstract][Full Text] [Related]
10. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
Fisher ER; Wang J; Bryant J; Fisher B; Mamounas E; Wolmark N
Cancer; 2002 Aug; 95(4):681-95. PubMed ID: 12209710
[TBL] [Abstract][Full Text] [Related]
11. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
Bidard FC; Vincent-Salomon A; Gomme S; Nos C; de Rycke Y; Thiery JP; Sigal-Zafrani B; Mignot L; Sastre-Garau X; Pierga JY;
Clin Cancer Res; 2008 Jun; 14(11):3306-11. PubMed ID: 18519757
[TBL] [Abstract][Full Text] [Related]
12. Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high-dose chemotherapy: the role of induction chemotherapy.
Vredenburgh JJ; Peters WP; Rosner G; DeSombre K; Johnston WW; Kamel A; Wu K; Bast RC
Bone Marrow Transplant; 1995 Dec; 16(6):815-21. PubMed ID: 8750275
[TBL] [Abstract][Full Text] [Related]
13. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.
Vredenburgh JJ; Silva O; Broadwater G; Berry D; DeSombre K; Tyer C; Petros WP; Peters WP; Bast RC
Biol Blood Marrow Transplant; 1997 Jun; 3(2):91-7. PubMed ID: 9267669
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy.
Patriarca F; Sacco C; Sperotto A; Geromin A; Damiani D; Fili C; Cerno M; Clochiatti L; Cartei G; Fanin R
Bone Marrow Transplant; 2003 May; 31(9):789-94. PubMed ID: 12732886
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
[TBL] [Abstract][Full Text] [Related]
16. Occult tumor cells detected in autologous blood stem cell harvests have no impact on 5 year outcomes for breast cancer patients with 4-9 positive nodes treated with adjuvant high-dose therapy and stem cell transplantation.
Reed E; Kessinger A; Murphy B; Tarantolo S; Traystman M; Sharp JG
Bone Marrow Transplant; 2003 Apr; 31(7):571-4. PubMed ID: 12692623
[TBL] [Abstract][Full Text] [Related]
17. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
18. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment.
Glück S; Ross AA; Layton TJ; Ostrander AB; Goldstein LC; Porter K; Ho AD
Biol Blood Marrow Transplant; 1997 Dec; 3(6):316-23. PubMed ID: 9502299
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
20. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens.
Stewart DA; Guo D; Morris D; Poon MC; Ruether BA; Jones AR; Klassen J; Auer I; Luider J; Chaudhry A; Brown C; Russell JA
Bone Marrow Transplant; 1999 Jan; 23(2):111-7. PubMed ID: 10197794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
